Abstract
As a part of our efforts to expand chemical diversity in the carbonic anhydrases inhibitors (CAIs), three small series of polyheterocyclic compounds (4-6) featuring the primary benzenesulfonamide moiety linked to bi/tricyclic scaffolds were investigated. Highly effective inhibitors against the target tumor-associated hCA IX (low nanomolar/subnanomolar potency levels) showing significant functional selectivity profile toward hCA I, II, and IV isozymes were identified. Molecular docking studies clarified the reasons behind the activity and selectivity of the new compounds.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Benzenesulfonamides
-
Carbonic Anhydrase II / antagonists & inhibitors*
-
Carbonic Anhydrase II / chemistry
-
Carbonic Anhydrase IX / antagonists & inhibitors*
-
Carbonic Anhydrase IX / chemistry
-
Carbonic Anhydrase Inhibitors / chemistry*
-
Carbonic Anhydrase Inhibitors / pharmacology*
-
Catalytic Domain
-
Drug Design*
-
Humans
-
Isoenzymes / antagonists & inhibitors
-
Isoenzymes / chemistry
-
Models, Molecular
-
Sulfonamides / chemistry*
-
Sulfonamides / pharmacology*
Substances
-
Carbonic Anhydrase Inhibitors
-
Isoenzymes
-
Sulfonamides
-
Carbonic Anhydrase II
-
Carbonic Anhydrase IX